Sonoma Pharmaceuticals (SNOA) Debt to Equity (2011 - 2025)

Sonoma Pharmaceuticals' Debt to Equity history runs 15 years deep, the most recent figure standing at $0.01 for Q3 2025.

• In Q3 2025, Debt to Equity fell 3.48% year-over-year to $0.01; the TTM figure through Sep 2025 stood at $0.01 (down 3.48% YoY), while the FY2025 annual figure was $0.05, down 5.24% from the prior year.
• Debt to Equity was $0.01 for Q3 2025 at Sonoma Pharmaceuticals, down from $0.03 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.36 in Q1 2021 to a low of $0.0 in Q4 2022.
• Historically, Debt to Equity has averaged $0.06 across 5 years, with a median of $0.04 in 2024.
• Biggest YoY gain for Debt to Equity was 315.54% in 2021; the steepest drop was 85.23% in 2021.
• A 5-year view of Debt to Equity shows it stood at $0.02 in 2021, then sank by 84.46% to $0.0 in 2022, then soared by 143.67% to $0.01 in 2023, then surged by 133.02% to $0.02 in 2024, then slipped by 3.48% to $0.01 in 2025.
• The last three Debt to Equity figures came in at $0.01 (Q3 2025), $0.03 (Q2 2025), and $0.05 (Q1 2025), per Business Quant data.